Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries(Angeles Clinic and Research Institute), Robert M. Elashoff(University of California, Los Angeles), Richard Hoefer(Sentara Norfolk General Hospital), Patrick Terheyden(University Hospital Schleswig-Holstein), Carlo Riccardo Rossi(University of Padua), Jeffrey D. Wayne(Northwestern University), Rogerio I. Neves(Saint John's Health Center), Heather B. Neuman(University of Wisconsin–Madison), Michael A. Henderson(Peter MacCallum Cancer Centre), Anja Gesierich(University of Michigan), B. Mark Smithers(The University of Queensland), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Adam C. Berger(Fox Chase Cancer Center), Harald J. Hoekstra(University Medical Center Groningen), Jonathan S. Zager(Moffitt Cancer Center), Douglas B. Johnson(Vanderbilt University Medical Center), Alastair D. MacKenzie Ross(Guy's and St Thomas' NHS Foundation Trust), Eddy C. Hsueh(Saint Louis University), Peter D. Beitsch(Dallas Surgical Group), Robert H.I. Andtbacka(Huntsman Cancer Institute), John F. Thompson(Melanoma Institute Australia), Tara L. Huston(Stony Brook University Hospital), Maurice Matter(University Hospital of Lausanne), Doreen M. Agnese(Saint John's Health Center), Frances C. Wright(Saint John's Health Center), Edward A. Levine(Wake Forest University), Schlomo Schneebaum(Tel Aviv Sourasky Medical Center), Erwin Schultz(Nuremberg Hospital), Lisa K. Jacobs(Johns Hopkins University), Marc Moncrieff(Norfolk and Norwich University Hospital), Peter Hersey(The University of Sydney), Tawnya L. Bowles(Intermountain Medical Center), Michel W.J.M. Wouters(The Netherlands Cancer Institute), Steven D. Bines(Rush University Medical Center), Tiina Jahkola(Helsinki University Hospital), Jeffrey M. Farma(Fox Chase Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Richard J. Barth(Dartmouth–Hitchcock Medical Center), Kelly M. McMasters(University of Louisville), Reinhard Dummer(University Hospital of Zurich), Michael S. Sabel(Michigan Cancer Research Consortium), Christian Ingvar(Lund University), Gregory McKinnon(Saint John's Health Center), Darius C. Desai(St. Luke's University Health Network), David R. Byrd(University of Washington), Steven D. Trocha(Thomas Jefferson University), Alistair J. Cochran(Western Infirmary), Sergi Vidal‐Sicart(Hospital Clínic de Barcelona), Nicola Mozzillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Charlotte E. Ariyan(Memorial Sloan Kettering Cancer Center), John M. Kane(University of North Carolina at Chapel Hill)
Cited by 1,379
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k